Keiji Masuda

Dr. Keiji Masuda

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
KMKeiji Masuda
Keiji Masuda
XHXu Han
Xu Han
HKHiroki Kato
Hiroki Kato
HSHiroshi Sato
Hiroshi Sato
YZYu Zhang
Yu Zhang
SFSatoshi Fukumoto
Satoshi Fukumoto
A subpopulation of mesenchymal stem cells, developmentally derived from multipotent neural crest cells that form multiple facial tissues, resides within the dental pulp of human teeth. These stem cells show high proliferative capacity in vitro and are multipotent, including adipogenic, myogenic, osteogenic, chondrogenic, and neurogenic potential. Teeth containing viable cells are harvested via minimally invasive procedures, based on various clinical diagnoses, but then usually discarded as medical waste, indicating the relatively low ethical considerations to reuse these cells for medical applications. Previous studies have demonstrated that stem cells derived from healthy subjects are an excellent source for cell-based medicine, tissue regeneration, and bioengineering. Furthermore, stem cells donated by patients affected by genetic disorders can serve as in vitro models of disease-specific genetic variants, indicating additional applications of these stem cells with high plasticity. This review discusses the benefits, limitations, and perspectives of patient-derived dental pulp stem cells as alternatives that may complement other excellent, yet incomplete stem cell models, such as induced pluripotent stem cells, together with our recent data.

1 December 2018 in Biochemistry and Biophysics Reports
Verified
Journal Article
Open access
HNHuong Thi Nguyen Nguyen
Huong Thi Nguyen Nguyen
HKHiroki Kato
Hiroki Kato
KMKeiji Masuda
Keiji Masuda
HYHaruyoshi Yamaza
Haruyoshi Yamaza
YHYuta Hirofuji
Yuta Hirofuji
KNKazuaki Nonaka
Kazuaki Nonaka
Autism spectrum disorder (ASD) is a highly heterogeneous neurodevelopmental disorder characterized by impaired social interactions, restrictive interests, and repetitive stereotypic behaviors. Among the various mechanisms underlying the pathogenesis of ASD, dysfunctions of dopaminergic signaling and mitochondria have been hypothesized to explain the core symptoms of children with ASD. However, only a few studies focusing on the pathological association between dopaminergic neurons (DN) and mitochondria in ASD have been performed using patient-derived stem cells and in vitro differentiated neurons. Stem cells from human exfoliated deciduous teeth (SHED) are neural crest-derived mesenchymal stem cells present in the dental pulp of exfoliated deciduous teeth; these cells can differentiate into dopaminergic neurons (DN) in vitro. This study aimed to investigate the pathological association between development of DN and mitochondria in ASD by using SHED as a disease- or patient-specific cellular model. The SHED obtained from three children with ASD and three typically developing children were differentiated into DN, and the neurobiology of these cells was examined. The DN derived from children with ASD showed impaired neurite outgrowth and branching, associated with decreased mitochondrial membrane potential, ATP production, number of mitochondria within the neurites, amount of mitochondria per cell area and intracellular calcium level. In addition, impaired neurite outgrowth and branching of ASD-derived DN were not improved by brain-derived neurotrophic factor (BDNF), suggesting impairment of the BDNF signaling pathway in ASD. These results imply that intracerebral dopamine production may have decreased in these children. The earliest age at which deciduous teeth spontaneously exfoliate in humans, and SHED can be noninvasively collected, is approximately 6 years. Our results suggest that in vitro analysis of SHED-derived DN obtained from children with ASD provides neurobiological information that may be useful in determining treatment strategies in the early stages of ASD.

1 June 2019 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
HNHuong Thi Nguyen Nguyen
Huong Thi Nguyen Nguyen
HKHiroki Kato
Hiroki Kato
HSHiroshi Sato
Hiroshi Sato
HYHaruyoshi Yamaza
Haruyoshi Yamaza
YSYasunari Sakai
Yasunari Sakai
KMKeiji Masuda
Keiji Masuda

1 April 2000 in Smart Materials and Structures
Verified
Journal Article
Closed access
YNYoshiya Nakamura
Yoshiya Nakamura
MNMasanao Nakayama
Masanao Nakayama
KMKeiji Masuda
Keiji Masuda
KTKiyoshi Tanaka
Kiyoshi Tanaka
MYMasashi Yasuda
Masashi Yasuda
TFTakafumi Fujita
Takafumi Fujita

1 September 2019 in Biochemistry and Biophysics Reports
Verified
Journal Article
Open access
KNKentaro Nonaka
Kentaro Nonaka
XHXu Han
Xu Han
HKHiroki Kato
Hiroki Kato
HSHiroshi Sato
Hiroshi Sato
HYHaruyoshi Yamaza
Haruyoshi Yamaza
KMKeiji Masuda
Keiji Masuda
Metatropic dysplasia is a congenital skeletal dysplasia characterized by severe platyspondyly, dumbbell-like deformity of long tubular bones, and progressive kyphoscoliosis with growth. It is caused by mutations in the gene TRPV4, encoding the transient receptor potential vanilloid 4, which acts as a calcium channel. Many heterozygous single base mutations of this gene have been associated with the disorder, showing autosomal dominant inheritance. Although abnormal endochondral ossification has been observed by histological examination of bone in a patient with lethal metatropic dysplasia, the etiology of the disorder remains largely unresolved. As dental pulp stem cells (DPSCs) are mesenchymal stem cells that differentiate into bone lineage cells, DPSCs derived from patients with congenital skeletal dysplasia might be useful as a disease-specific cellular model for etiological investigation. The purpose of this study was to clarify the pathological association between TRPV4 mutation and chondrocyte differentiation by analyzing DPSCs from a patient with non-lethal metatropic dysplasia. We identified a novel heterozygous single base mutation, c.1855C>T in TRPV4. This was predicted to be a missense mutation, p.L619F, in putative transmembrane segment 5. The mutation was repaired by CRISPR/Cas9 system to obtain isogenic control DPSCs for further analysis. The expression of stem cell markers and fibroblast-like morphology were comparable between patient-derived mutant and control DPSCs, although expression of TRPV4 was lower in mutant DPSCs than control DPSCs. Despite the lower TRPV4 expression in mutant DPSCs, the intracellular Ca2+ level was comparable at the basal level between mutant and control DPSCs, while its level was markedly higher following stimulation with 4α-phorbol 12,13-didecanoate (4αPDD), a specific agonist for TRPV4, in mutant DPSCs than in control DPSCs. In the presence of 4αPDD, we observed accelerated early chondrocyte differentiation and upregulated mRNA expression of SRY-box 9 (SOX9) in mutant DPSCs. Our findings suggested that the novel missense mutation c.1855C>T of TRPV4 was a gain-of-function mutation leading to enhanced intracellular Ca2+ level, which was associated with accelerated chondrocyte differentiation and SOX9 upregulation. Our results also suggest that patient-derived DPSCs can be a useful disease-specific cellular model for elucidating the pathological mechanism of metatropic dysplasia.

1 April 2018 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
SHSaki Hirofuji
Saki Hirofuji
YHYuta Hirofuji
Yuta Hirofuji
HKHiroki Kato
Hiroki Kato
KMKeiji Masuda
Keiji Masuda
HYHaruyoshi Yamaza
Haruyoshi Yamaza
KNKazuaki Nonaka
Kazuaki Nonaka